65. 原発性免疫不全症候群 Primary immunodeficiency Clinical trials / Disease details
臨床試験数 : 482 / 薬物数 : 653 - (DrugBank : 119) / 標的遺伝子数 : 92 - 標的パスウェイ数 : 212
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03232203 (ClinicalTrials.gov) | April 12, 2018 | 25/7/2017 | Evaluating the Effectiveness of STRIMVELIS Risk Minimization Measures (RMMs) | Evaluation of Referring HCPs' and Parents'/Carers' Understanding of Specific Risks Associated With Strimvelis™ Treatment | Severe Combined Immunodeficiency Due to ADA Deficiency | Drug: STRIMVELIS | Orchard Therapeutics | NULL | Completed | 18 Years | N/A | All | 16 | Italy | |
| 2 | EUCTR2017-001731-39-IT (EUCTR) | 12/10/2017 | 02/07/2020 | Retroviral insertion site methodology study | Methodology study to investigate the utility of retroviral insertion site analysis in samples from subjects treated with Strimvelis™ gene therapy - Retroviral insertion site methodology study | Adenosine deaminase (ADA) deficiency severe combined immunodeficiency MedDRA version: 20.1;Level: LLT;Classification code 10066367;Term: Adenosine deaminase deficiency;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Trade Name: Strimvelis Product Name: Strimvelis Product Code: [NA] | Orchard Therapeutics (Europe) Ltd | NULL | Not Recruiting | Female: yes Male: yes | 15 | Phase 4 | Turkey;Switzerland;Italy |